Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma

Medical Hypotheses

Volumn 79, Issue 5, 2012, Pages 678-697

  Fiorino, S ^a   Lorenzini, S ^b   Masetti, M ^c   Deleonardi, G ^c   Grondona, A G ^c   Silvestri, T ^c   Chili, E ^a   Del Prete, P ^a   Bacchi Reggiani, L ^d   Cuppini, A ^a   Jovine, E ^c  

^a Ospedale di Budrio   (Italy)

^b Ospedale di Ravenna   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; NOTCH RECEPTOR; PROSTAGLANDIN E2; RAS PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ACUTE PANCREATITIS; APOPTOSIS; ARTICLE; CANCER RISK; CD4+ CD25+ T LYMPHOCYTE; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CHRONIC PANCREATITIS; CYTOSKELETON; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EPSTEIN BARR VIRUS; HEPATITIS B; HEPATITIS C; HISTONE MODIFICATION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; MACROPHAGE; NONHUMAN; OBSERVATIONAL STUDY; PANCREAS ADENOCARCINOMA; PATHOGENESIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; STELLATE CELL; STUDY DESIGN; SUPPRESSOR CELL; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR MICROENVIRONMENT; TUMOR VIRUS; UPREGULATION; VERRUCA VULGARIS; VIRUS; WART VIRUS;

ADENOCARCINOMA; HEPATITIS B; HEPATITIS C; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84867332775     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.08.008     Document Type: Article

References (279)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. AIRT Working Group Italian cancer figures - report 2006: 1. Incidence, mortality and estimates. Epidemiol Prev 2006, 30(1 Suppl. 2):8-10. 12-28, 30-101.
4. Imamura M., Doi R., Imaizumi T., et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004, 136(5):1003-1011.
5. Gouma D.J., van Geenen R.C., van Gulik T.M., et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000, 232(6):786-795.
6. Schnelldorfer T., Ware A.L., Sarr M.G., et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg 2008, 247(3):456-462.
7. Oettle H., Post S., Neuhaus P., Gellert K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277.
8. Esposito I., Kleeff J., Bergmann F., et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008, 15(6):1651-1660.
9. Kleeff J., Reiser C., Hinz U., et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007, 245(4):566-572.
10. Winter J.M., Cameron J.L., Campbell K.A., et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006, 10(9):1199-1210.
11. Richter A., Niedergethmann M., Sturm J.W., Lorenz D., Post S., Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003, 27:324-329.
12. Li D., Day R.S., Bondy M.L., Sinha R., et al. Dietary mutagen exposure and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(4):655-661.
13. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362(17):1605-1617.
14. Larghi A., Verna E.C., Lecca P.G., Costamagna G. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 2009, 15(6):1907-1914.
15. Jacobs E.J., Rodriguez C., Newton C.C., et al. Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes Control 2009, 20(8):1261-1269.
16. Hassan M.M., Bondy M.L., Wolff R.A., et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007, 102(12):2696-2707.
17. Apte M., Pirola R., Wilson J. New insights into alcoholic pancreatitis and pancreatic cancer. J Gastroenterol Hepatol 2009, 24(Suppl. 3):S51-S56.
18. Chari S.T., Leibson C.L., Rabe K.G., et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008, 134(1):95-101.
19. Pannala R., Leibson C.L., Rabe K.G., et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009, 104(9):2318-2325.
20. Lowenfels A.B., Maisonneuve P., Lankisch P.G. Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterol Clin North Am 1999, 28:673-685.
21. Talamini G., Falconi M., Bassi C., et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999, 94(5):1253-1260.
22. Ishikawa T. Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2010, 16(20):2463-2467.
23. Centers for Disease Control and Prevention (CDC) Hepatocellular carcinoma United States. Hepatocellular carcinoma - United States, 2001-2006 2010, 59(17):517-520.
24. Castello G., Scala S., Palmieri G., Curley S.A., Izzo F. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol 2010, 134(3):237-250.
25. Ulcickas Yood M., Quesenberry C.P., Guo D., et al. Incidence of non-Hodgkin's lymphoma among ndividuals with chronic hepatitis B virus infection. Hepatology 2007, 46(1):107-112.
26. Dal Maso L., Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006, 15(11):2078-2085.
27. Shin H.R., Oh J.K., Masuyer E., et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010, 101(3):579-585.
28. Astbury K., Turner M.J. Human papillomavirus vaccination in the prevention of cervical neoplasia. Int J Gynecol Cancer 2009, 19(9):1610-1613.
29. Lizano M., Berumen J., García-Carrancá A. HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res 2009, 40(6):428-434.
30. Muñoz N., Bosch F.X., de Sanjosé S., et al. International agency for research on cancer multicenter cervical cancer study group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
31. Sunil M., Reid E., Lechowicz M.J. Update on HHV-8-associated malignancies. Curr Infect Dis Rep 2010, 12(2):147-154.
32. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990, 55:133-270.
33. Shah K.M., Young L.S. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin Microbiol Infect 2009, 15(11):982-988.
34. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000, 53(5):255-261.
35. Cáceres W., Cruz-Amy M., Díaz-Meléndez V. AIDS-related malignancies: revisited. P R Health Sci J 2010, 29(1):70-75.
36. Mounier N., Spina M., Spano J.P. Hodgkin lymphoma in HIV positive patients. Curr HIV Res 2010, 8(2):141-146.
37. Jackson L., Evers B.M. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 2006, 130:39-65.
38. Schottenfeld D., Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006, 56(2):69-83.
39. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121(11):2373-2380.
40. Kuper H., Adami H.O., Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000, 248(3):171-183.
41. Onyeagocha C., Hossain M.S., Kumar A., Jones R.M., Roback J., Gewirtz A.T. Latent cytomegalovirus infection exacerbates experimental colitis. Am J Pathol 2009, 175(5):2034-2042.
42. Pironi L., Bonvicini F., Gionchetti P., et al. Parvovirus b19 infection localized in the intestinal mucosa and associated with severe inflammatory bowel disease. J Clin Microbiol 2009, 47(5):1591-1595.
43. Acevedo-Nuño E., González-Ojeda A., Vázquez-Camacho G., Balderas-Peña Luz Ma A., Moreno-Villa H., Montoya-Fuentes H. Human papillomavirus DNA and protein in tissue samples of oesophageal cancer, Barrett's oesophagus and oesophagitis. Anticancer Res 2004, 24(2C):1319-1323.
44. Iyer A., Rajendran V., Adamson C.S., Peng Z., Cooper K., Evans M.F. Human papillomavirus is detectable in Barrett's esophagus and esophageal carcinoma but is unlikely to be of any etiologic significance. J Clin Virol 2011, 50(3):205-208.
45. Rajendra S., Robertson I.K. Similar immunogenetics of Barrett's oesophagus and cervical neoplasia: is HPV the common denominator?. J Clin Pathol 2010, 63(1):1-3.
46. Sakorafas G.H., Tsiotou A.G. Etiology and pathogenesis of acute pancreatitis: current concepts. J Clin Gastroenterol 2000, 30(4):343-356.
47. Jain P., Nijhawan S., Rai R.R., Nepalia S., Mathur A. Acute pancreatitis in acute viral hepatitis. World J Gastroenterol 2007, 13(43):5741-5744.
48. Alvares-Da-Silva M.R., Francisconi C.F., Waechter F.L. Acute hepatitis C complicated by pancreatitis: another extrahepatic manifestation of hepatitis C virus?. J Viral Hepat 2000, 7(1):84-86.
49. Bhagat S., Wadhawan M., Sud R., Arora A. Hepatitis viruses causing pancreatitis and hepatitis: a case series and review of literature. Pancreas 2008, 36(4):424-427.
50. Parenti D.M., Steinberg W., Kang P. Infectious causes of acute pancreatitis. Pancreas 1996, 13(4):356-371.
51. Khanna S., Vij J.C. Severe acute pancreatitis due to hepatitis A virus infection in a patient of acute viral hepatitis. Trop Gastroenterol 2003, 24(1):25-26.
52. Yuen M.F., Chan T.M., Hui C.K., Chan A.O., Ng I.O., Lai C.L. Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. J Viral Hepat 2001, 8(6):459-464.
53. Joshi R.A., Probstein J.G., Blumenthal H.T. A survey of experiences with three hundred clinical and one hundred and eight autopsy cases of acute pancreatitis. Am Surg 1957, 23(1):34-42.
54. Jaroszewicz J., Flisiak R., Kalinowska A., Wierzbicka I., Prokopowicz D. Acute hepatitis E complicated by acute pancreatitis: a case report and literature review. Pancreas 2005, 30(4):382-384.
55. Teixidor H.S., Honig C.L., Norsoph E., Albert S., Mouradian J.A., Whalen J.P. Cytomegalovirus infection of the alimentary canal: radiologic findings with pathologic correlation. Radiology 1987, 163(2):317-323.
56. Iwasaki T., Tashiro A., Satodate R., Sata T., Kurata T. Acute pancreatitis with cytomegalovirus infection. Acta Pathol Jpn 1987, 37(10):1661-1668.
57. Lal S.M., Fowler D., Losasso C.J., Berg G.G. Coxsackie virus-induced acute pancreatitis in a long-term dialysis patient. Am J Kidney Dis 1988, 11(5):434-436.
58. Shintaku M., Umehara Y., Iwaisako K., Tahara M., Adachi Y. Herpes simplex pancreatitis. Arch Pathol Lab Med 2003, 127(2):231-234.
59. Kirschner S., Raufman J.P. Varicella pancreatitis complicated by pancreatic pseudocyst and duodenal obstruction. Dig Dis Sci 1988, 33(9):1192-1195.
60. Franco J., Fernandes R., Oliveira M., et al. Acute pancreatitis associated with varicella infection in an immunocompetent child. J Paediatr Child Health 2009, 45(9):547-548.
61. Gerstner E.R., Batchelor T.T. Primary central nervous system lymphoma. Arch Neurol 2010, 67(3):291-297.
62. Katakura Y., Yotsuyanagi H., Hashizume K., et al. Pancreatic involvement in chronic viral hepatitis. World J Gastroenterol 2005, 11(23):3508-3513.
63. Pezzilli R., Andreone P., Morselli-Labate A.M., et al. Serum pancreatic enzyme concentrations in chronic viral liver diseases. Dig Dis Sci 1999, 44(2):350-355.
64. Yan F.M., Chen A.S., Hao F., et al. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol 2000, 6(6):805-811.
65. Mason A., Wick M., White H., Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993, 18(4):781-789.
66. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev 2007, 20(3):426-439.
67. Hoefs J.C., Renner I.G., Askhcavai M., Redeker A.G. Hepatitis B surface antigen in pancreatic and biliary secretions. Gastroenterology 1980, 79(2):191-194.
68. Redeker A.G., Hoefs J.C., Renner I.G., Ashcavai M. Does hepatitis B virus grow outside the liver. Gastroenterology 1980, 79(3):600.
69. Shimoda T., Shikata T., Karasawa T., Tsukagoshi S., Yoshimura M., Sakurai I. Light microscopic localization of hepatitis B virus antigens in the human pancreas. Possibility of multiplication of hepatitis B virus in the human pancreas. Gastroenterology 1981, 81(6):998-1005.
70. Dejean A., Lugassy C., Zafrani S., Tiollais P., Brechot C. Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. J Gen Virol 1984, 65(Pt. 3):651-655.
71. Hohenberger P. The pancreas as target organ for hepatitis B virus-immunohistological detection of HBsAg in pancreatic carcinoma and chronic pancreatitis. Leber Magen Darm 1985, 15(2):58-63.
72. Cavallari A., Vivarelli M., D'Errico A., et al. Fatal necrotizing pancreatitis caused by hepatitis B virus infection in a liver transplant recipient. J Hepatol 1995, 22(6):685-690.
73. Laskus T., Radkowski M., Wang L.F., Vargas H., Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology 1998, 28(5):1398-1401.
74. Sugiyama K., Kato N., Ikeda M., et al. Hepatitis C virus in pelvic lymph nodes and female reproductive organs. Jpn J Cancer Res 1997, 88(10):925-927.
75. Chen M.Y., Huang Z.Q., Chen L.Z., Gao Y.B., Peng R.Y., Wang D.W. Detection of hepatitis C virus NS5 protein and genome in Chinese carcinoma of the extrahepatic bile duct and its significance. World J Gastroenterol 2000, 6(6):800-804.
76. Hassan M.M., Li D., El-Deeb A.S., et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008, 26(28):4557-4562.
77. Berrington de Gonzalez A., Yun J.E., Lee S.Y., Klein A.P., Jee S.H. Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study. Cancer Epidemiol Biomarkers Prev 2008, 17(2):359-364.
78. Sherman M. Pancreatic cancer in chronic hepatitis B. Liver Int 2010, 30(3):339-341.
79. Hassan M.M. Association between hepatitis B virus and pancreatic cancer. Author Reply J Clin Oncol 2009, 27(4):648-649.
80. Iloeje U.H., Yang H.I., Jen C.L., et al. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 2010, 30(3):423-429.
81. El-Serag H.B., Engels E.A., Landgren O., et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of US veterans. Hepatology 2009, 49(1):116-123.
82. Zaret K.S., Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 2008, 322(5907):1490-1494.
83. Zaret K.S. Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nat Rev Genet 2008, 9(5):329-340.
84. Wandzioch E., Zaret K.S. Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. Science 2009, 324(5935):1707-1710.
85. Wieland S.F., Chisari F.V. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005, 79(15):9369-9380.
86. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87(Pt. 6):1439-1449.
87. Mogensen T.H., Paludan S.R. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev 2001, 65(1):131-150.
88. Hsu H.Y., Chang M.H., Ni Y.H., Lee P.I. Cytokine release of peripheral blood mononuclear cells in children with chronic hepatitis B virus infection. J Pediatr Gastroenterol Nutr 1999, 29(5):540-545.
89. Andus T., Bauer J., Gerok W. Effects of cytokines on the liver. Hepatology 1991, 13(2):364-375.
90. Chisari F.V., Cytotoxic T. Cells and viral hepatitis. J Clin Invest 1997, 99(7):1472-1477.
91. Hamada S., Masamune A., Takikawa T., et al. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem Biophys Res Commun 2012, 421(2):349-354.
92. Bachem M.G., Zhou S., Buck K., Schneiderhan W., Siech M. Pancreatic stellate cells-role in pancreas cancer. Langenbecks Arch Surg 2008, 393(6):891-900.
93. Ceyhan G.O., Demir I.E., Altintas B., et al. Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem Biophys Res Commun 2008, 374(3):442-447.
94. Hingorani S.R., Petricoin E.F., Maitra A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4(6):437-450.
95. Tuveson D.A., Shaw A.T., Willis N.A., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004, 5(4):375-387.
96. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001, 25(5):579-586.
97. Maitra A., Fukushima N., Takaori K., Hruban R.H. Precursors to invasive pancreatic cancer. Adv Anat Pathol 2005, 12(2):81-91.
98. Sipos B., Frank S., Gress T., Hahn S., Klöppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 2009, 9(1-2):45-54.
99. Real F.X. A "catastrophic hypothesis" for pancreas cancer progression. Gastroenterology 2003, 124(7):1958-1964.
100. Rooman I., Real F.X. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development?. Gut 2012, 61(3):449-458.
101. Hruban R.H., Takaori K., Klimstra D.S., et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004, 28(8):977-987.
102. Singh M., Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007, 7(1):9-19.
103. Jamieson J.D. Prospectives for cell and organ culture systems in the study of pancreatic carcinoma. J Surg Oncol 1975, 7(2):139-141.
104. Habbe N., Shi G., Meguid R.A., et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 2008, 105(48):18913-18918.
105. Parsa I., Longnecker D.S., Scarpelli D.G., Pour P., Reddy J.K., Lefkowitz M. Ductal metaplasia of human exocrine pancreas and its association with carcinoma. Cancer Res 1985, 45(3):1285-1290.
106. Reichert M., Rustgi A.K. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 2011, 121(12):4572-4578. 10.1172/JCI57131.
107. Carrière C., Young A.L., Gunn J.R., Longnecker D.S., Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun 2009, 382(3):561-565.
108. Cerec V., Glaise D., Garnier D., et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007, 45(4):957-967.
109. Shen C.N., Slack J.M., Tosh D. Molecular basis of transdifferentiation of pancreas to liver. Nat Cell Biol 2000, 2(12):879-887.
110. Rao M.S., Subbarao V., Reddy J.K. Induction of hepatocytes in the pancreas of copper-depleted rats following copper repletion. Cell Differ 1986, 18(2):109-117.
111. Reddy J.K., Rao M.S., Qureshi S.A., Reddy M.K., Scarpelli D.G., Lalwani N.D. Induction and origin of hepatocytes in rat pancreas. J Cell Biol 1984, 98(6):2082-2090.
112. Dabeva M.D., Hwang S.G., Vasa S.R., et al. Differentiation of pancreatic epithelial progenitor cells into hepatocytes following transplantation into rat liver. Proc Natl Acad Sci USA 1997, 94(14):7356-7361.
113. Wang R.Y., Shen C.N., Lin M.H., Tosh D., Shih C. Hepatocyte-like cells transdifferentiated from a pancreatic origin can support replication of hepatitis B virus. J Virol 2005, 79(20):13116-13128.
114. Nitsche C., Simon P., Weiss F.U., et al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig Dis 2011, 29(2):235-242.
115. Raimondi S., Lowenfels A.B., Morselli-Labate A.M., Maisonneuve P., Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010, 24(3):349-358.
116. Aichler M., Seiler C., Tost M., et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 2012, 226(5):723-734. 10.1002/path.3017.
117. Criscimanna A., Speicher J.A., Houshmand G., Fendrich V., Esni F., Chen H., et al. Duct cells contribute to regeneration of endocrine and acinar cells following pancreatic damage in adult mice. Gastroenterology 2011, 141(4):1451-1462. 1462e1-1462e6.
118. Löhr M., Maisonneuve P., Lowenfels A.B. K-Ras mutations and benign pancreatic disease. Int J Pancreatol 2000, 27(2):93-103.
119. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53(4):549-554.
120. Tuveson D.A., Hingorani S.R. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005, 70:65-72.
121. De La O.J.P., Emerson L.L., Goodman J.L., et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 2008, 105(48):18907-18912.
122. Bardeesy N., Aguirre A.J., Chu G.C., et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006, 103(15):5947-5952.
123. Guerra C., Schuhmacher A.J., Cañamero M., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11(3):291-302.
124. Brembeck F.H., Schreiber F.S., Deramaudt T.B., et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res 2003, 63(9):2005-2009.
125. Tanaka H., Fukamachi K., Futakuchi M., et al. Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats. Cancer Sci 2010, 101(2):341-346.
126. Guerra C., Collado M., Navas C., et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19(6):728-739.
127. Ji B., Tsou L., Wang H., Gaiser S., et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009, 137(3):1072-1082. 1082e1-1082e6.
128. Logsdon C.D., Ji B. Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clin Gastroenterol Hepatol 2009, 7(Suppl. 11):S40-S43.
129. Swarbrick A., Roy E., Allen T., Bishop J.M. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA 2008, 105(14):5402-5407.
130. Morris J.P., Cano D.A., Sekine S., Wang S.C., Hebrok M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest 2010, 120(2):508-520. 10.1172/JCI40045.
131. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007, 6(4):1186-1197.
132. Luo G., Long J., Zhang B., et al. Stroma and pancreatic ductal adenocarcinoma: an interaction loop. Biochim Biophys Acta 2012, 1826(1):170-178.
133. Imamura T., Iguchi H., Manabe T., et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas 1995, 11(4):357-364.
134. Talar-Wojnarowska R., Gasiorowska A., Smolarz B., Romanowicz-Makowska H., Kulig A., Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009, 54(3):683-689.
135. Chen J., Huang X.F. Interleukin-6 promotes carcinogenesis through multiple signal pathways. Comment on: clinical significance of interleukin-6 gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009, 54(6):1373-1374.
136. Truty M.J., Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology 2007, 7(5-6):423-435.
137. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007, 67(19):9518-9527.
138. Buchholz M., Kestler H.A., Holzmann K., et al. Transcriptome analysis of human hepatic and pancreatic stellate cells: organ-specific variations of a common transcriptional phenotype. J Mol Med (Berl) 2005, 83(10):795-805.
139. Erkan M., Weis N., Pan Z., et al. Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer 2010, 9:88.
140. Bharadwaj U., Li M., Zhang R., Chen C., Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007, 67(11):5479-5488.
141. Hegde S., Pahne J., Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J 2004, 18(12):1439-1441.
142. Hinz S., Pagerols-Raluy L., Oberg H.H., et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007, 67(17):8344-8350.
143. Baratelli F., Lin Y., Zhu L., Yang S.C., et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005, 175(3):1483-1490.
144. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14(21):6735-6741.
145. Cheng A.S., Chan H.L., Leung W.K., et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004, 17:1169-1179.
146. Gong G., Waris G., Tanveer R., Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001, 98:9599-9604.
147. Waris G., Siddiqui A. HCV stimulates the expression of cyclooxygenase-2 via oxidative stress: role of PGE2 in RNA replication. J Virol 2005, 79:9725-9734.
148. Murata M., Matsuzaki K., Yoshida K., et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009, 49:1203-1217.
149. Lin W., Tsai W.L., Shao R.X., et al. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010, 138:2509-2518.
150. Waris G., Huh K.W., Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kB via oxidative stress. Mol Cell Biol 2001, 22:7721-7730.
151. Waris G., Tardif K.D., Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 2002, 64:1425-1430.
152. Paterlini-Bréchot P., Saigo K., Murakami Y., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22(25):3911-3916.
153. Feitelson M.A., Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007, 252(2):157-170.
154. Crespo P., León J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 2000, 57(11):1613-1636.
155. Plowman S.J., Williamson D.J., O'Sullivan M.J., et al. While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol 2003, 23(24):9245-9250.
156. Calvisi D.F., Ladu S., Gorden A., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130(4):1117-1128.
157. Macdonald A., Crowder K., Street A., McCormick C., Saksela K., Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem 2003, 278(20):17775-17784.
158. Bose S., Sakhuja P., Bezawada L., et al. Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling. J Gastroenterol Hepatol 2011, 26(1):135-144.
159. Benn J., Su F., Doria M., Schneider R.J. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996, 70(8):4978-4985.
160. Bahnassi A.A., Zekri A.R., El-Houssini S., et al. Hepatitis C virus-NS3P in relation to p53, p21waf, mdm2, p21-ras and c-erbB2 in hepatocarcinogenesis. J Gastroenterol Hepatol 2005, 20(11):1731-1740.
161. Oishi N., Shilagardi K., Nakamoto Y., Honda M., Kaneko S., Murakami S. Hepatitis B virus X protein overcomes oncogenic RAS-induced senescence in human immortalized cells. Cancer Sci 2007, 98(10):1540-1548.
162. Pasca di Magliano M., Sekine S., Ermilov A., et al. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 2006, 20(22):3161-3173.
163. Kawahira H., Scheel D.W., Smith S.B., German M.S., Hebrok M. Hedgehog signaling regulates expansion of pancreatic epithelial cells. Dev Biol 2005, 280(1):111-121.
164. Fendrich V., Oh E., Bang S., et al. Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. Neoplasia 2011, 13(10):923-930.
165. Pereira Tde A., Witek R.P., Syn W.K., et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest 2010, 90(12):1690-1703.
166. Kim H.Y., Cho H.K., Hong S.P., Cheong J. Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells. Cancer Lett 2011, 309(2):176-184.
167. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci 2007, 64(21):2746-2762.
168. Iwai A., Takegami T., Shiozaki T., Miyazaki T. Hepatitis C virus NS3 protein can activate the Notch-signaling pathway through binding to a transcription factor, SRCAP. PLoS One 2011, 6(6):e20718.
169. Xu J., Yun X., Jiang J., et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology 2010, 52(1):142-154.
170. Heldin C.H., Landström M., Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009, 21(2):166-176.
171. Inman G.J. Switching TGFβ from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011, 21(1):93-99.
172. Murata M., Matsuzaki K., Yoshida K., et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009, 49(4):1203-1217.
173. Matsuzaki K., Murata M., Yoshida K., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46(1):48-57.
174. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480.
175. Grigoryan T., Wend P., Klaus A., Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 2008, 22(17):2308-2341.
176. Liu J., Wang Z., Tang J., et al. Hepatitis C virus core protein activates Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line. Arch Virol 2011, 156(6):1013-1023.
177. Cha M.Y., Kim C.M., Park Y.M., Ryu W.S. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004, 39(6):1683-1693.
178. Park C.Y., Choi S.H., Kang S.M., et al. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 2009, 51(5):853-864.
179. Liu J., Ding X., Tang J., et al. Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One 2011, 6(11):e27496.
180. Hsieh A., Kim H.S., Lim S.O., Yu D.Y., Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling. Cancer Lett 2011, 300(2):162-172.
181. Erkan M., Adler G., Apte M.V., et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 2012, 61(2):172-178.
182. Martín-Vílchez S., Sanz-Cameno P., Rodríguez-Muñoz Y., et al. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 2008, 47(6):1872-1883.
183. Schulze-Krebs A., Preimel D., Popov Y., et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005, 129(1):246-258.
184. Liu X., Zhu S.T., You H., et al. Hepatitis B virus infects hepatic stellate cells and affects their proliferation and expression of collagen type I. Chin Med J (Engl) 2009, 122(12):1455-1461.
185. Yoo Y.G., Oh S.H., Park E.S., et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003, 278(40):39076-39084.
186. Abe M., Koga H., Yoshida T., et al. Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1α axis under hypoxic conditions. Hepatol Res 2012, 42(6):591-600. 10.1111/j.1872-034X.2011.00953.x.
187. Menke A., Philippi C., Vogelmann R., et al. Down-regulation of E-Cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 2001, 61:3508-3517.
188. Wilson G.K., Brimacombe C.L., Rowe I.A., et al. A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol 2012, 56(4):803-809.
189. Lara-Pezzi E., Roche S., Andrisani O.M., Sánchez-Madrid F., López-Cabrera M. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene 2001, 20(26):3323-3331.
190. Lara-Pezzi E., Majano P.L., Yáñez-Mó M., et al. Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. J Hepatol 2001, 34(3):409-415.
191. Giannelli G., Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 2005, 20(3):939-944.
192. Jung M.C., Pape G.R. Immunology of hepatitis B infection. Lancet Infect Dis 2002, 2(1):43-50.
193. Vingerhoets J., Michielsen P., Vanham G., et al. HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B. J Hepatol 1998, 28(1):8-16.
194. Fan X.G., Liu W.E., Li C.Z., et al. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm 1998, 7(4):295-297.
195. Ohno H., Kaneko S., Lin Y., Kobayashi K., Murakami S. Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J Med Virol 1999, 58(1):11-18.
196. Tacke R.S., Tosello-Trampont A., Nguyen V., Mullins D.W., Hahn Y.S. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem 2011, 286(12):10847-10855.
197. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001, 75(13):6209-6211.
198. Mahé Y., Mukaida N., Kuno K., et al. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem 1999, 266(21):13759-13763.
199. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12(12):1063-1073.
200. Raaben M., Einerhand A.W., Taminiau L.J., et al. Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection. Virol J 2007, 4:55.
201. Meydani S.N., Han S.N., Wu D. Vitamin E and immune response in the aged: molecular mechanisms and clinical implications. Immunol Rev 2005, 205:269-284.
202. Barrios-Rodiles M., Chadee K. Novel regulation of cyclooxygenase-2 expression and prostaglandin E2 production by IFN-gamma in human macrophages. J Immunol 1998, 161(5):2441-2448.
203. Larmonier N., Marron M., Zeng Y., et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007, 56(1):48-59.
204. Mahic M., Yaqub S., Johansson C.C., Taskén K., Aandahl E.M. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006, 177(1):246-254.
205. Nakamura K., Kitani A., Fuss I., et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004, 172(2):834-842.
206. Cheng A.S., Chan H.L., Leung W.K., et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2000, 17(10):1169-1179.
207. Waris G., Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005, 79(15):9725-9734.
208. Tai D.I., Tsai S.L., Chen Y.M., et al. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000, 31(3):656-664.
209. Waris G., Siddiqui A. Regulatory mechanisms of viral hepatitis B and C. J Biosci 2003, 28(3):311-321.
210. Okami J., Yamamoto H., Fujiwara Y., et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999, 5(8):2018-2024.
211. Kokawa A., Kondo H., Gotoda T., et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91(2):333-338.
212. Unitt E., Rushbrook S.M., Marshall A., et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005, 41(4):722-730.
213. Tjomsland V., Sandström P., Spångeus A., et al. Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?. BMC Cancer 2010, 10:87.
214. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12(18):5423-5434.
215. van der Molen R.G., Sprengers D., Binda R.S., et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004, 40(3):738-746.
216. Shiina M., Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008, 47(2):385-395.
217. Fuller M.J., Khanolkar A., Tebo A.E., Zajac A.J. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol 2004, 172(7):4204-4214.
218. Alcami A., Koszinowski U.H. Viral mechanisms of immune evasion. Mol Med Today 2000, 6(9):365-372.
219. Stoop J.N., van der Molen R.G., Baan C.C., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41(4):771-778.
220. Boettler T., Spangenberg H.C., Neumann-Haefelin C., et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005, 79(12):7860-7867.
221. Fu J., Xu D., Liu Z., et al. Wang FS. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132(7):2328-2339.
222. Yoshizawa K., Abe H., Kubo Y., et al. Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. Hepatol Res 2010, 40(2):179-187.
223. Hoechst B., Ormandy L.A., Ballmaier M., et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135(1):234-243.
224. Delpu Y., Hanoun N., Lulka H., et al. Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics 2011, 12(1):15-24.
225. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20(10):1218-1249.
226. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
227. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
228. Omura N., Goggins M. Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol 2009, 2(4):310-326.
229. Iorio M.V., Piovan C., Croce C.M. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010, 1799(10-12):694-701.
230. Nishida N., Nishimura T., Ito T., Komeda T., Fukuda Y., Nakao K. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol 2003, 18(3):897-909.
231. Sakakura C., Hagiwara A., Taniguchi H., et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer 1999, 80(12):2034-2039.
232. Jiang Z., Jhunjhunwala S., Liu J., et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012, 22(4):593-601.
233. Zemer R., Kitay Cohen Y., Naftaly T., Klein A. Presence of hepatitis C virus DNA sequences in the DNA of infected patients. Eur J Clin Invest 2008, 38(11):845-848.
234. Herceg Z., Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011, 727(3):55-61.
235. Lambert M.P., Paliwal A., Vaissière T., et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011, 54(4):705-715.
236. Formeister E.J., Tsuchiya M., Fujii H., Shpyleva S., Pogribny I.P., Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010, 692(1-2):26-33.
237. Deng Y.B., Nagae G., Midorikawa Y., et al. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2010, 101(6):1501-1510.
238. Um T.H., Kim H., Oh B.K., et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011, 54(5):939-947.
239. Feng Q., Stern J.E., Hawes S.E., Lu H., Jiang M., Kiviat N.B. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010, 88(2):287-292.
240. Park I.Y., Sohn B.H., Yu E., et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007, 132(4):1476-1494.
241. Zheng D.L., Zhang L., Cheng N., et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009, 50:377-387.
242. Benegiamo G., Vinciguerra M., Mazzoccoli G., Piepoli A., Andriulli A., Pazienza V. DNA methyltransferases 1 and 3b expression in huh-7 cells expressing HCV core protein of different genotypes. Dig Dis Sci 2012, 57(6):1598-1603.
243. Zhu Y.Z., Zhu R., Fan J., et al. Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. J Viral Hepat 2010, 17(2):98-107.
244. Lim J.S., Park S.H., Jang K.L. Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation. Cancer Lett 2012, 321(2):154-161.
245. Kim Y.J., Jung J.K., Lee S.Y., Jang K.L. Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. Cancer Lett 2010, 288(2):226-235.
246. Vivekanandan P., Thomas D., Torbenson M. Methylation regulates hepatitis B viral protein expression. J Infect Dis 2009, 199(9):1286-1291.
247. Vivekanandan P., Daniel H.D., Kannangai R., Martinez-Murillo F., Torbenson M. Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol 2010, 84(9):4321-4329.
248. Guo Y.H., Li Y.N., Zhao J.R., Zhang J., Yan Z. HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics 2011, 6(6):720-726.
249. Cougot D., Wu Y., Cairo S., et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem 2007, 282(7):4277-4287.
250. Shon J.K., Shon B.H., Park I.Y., et al. Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res 2009, 139(1):14-21.
251. Fernandez A.F., Esteller M. Viral epigenomes in human tumorigenesis. Oncogene 2010, 29(10):1405-1420.
252. Bock C.T., Schwinn S., Locarnini S., et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001, 307(1):183-196.
253. Christen V., Treves S., Duong F.H., Heim M.H. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007, 46(2):558-565.
254. Chowdhury D., Keogh M.C., Ishii H., Peterson C.L., Buratowski S., Lieberman J. Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 2005, 20(5):801-809.
255. Duong F.H., Filipowicz M., Tripodi M., La Monica N., Heim M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004, 126(1):263-277.
256. Christen V., Duong F., Bernsmeier C., Sun D., Nassal M., Heim M.H. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 2007, 81(1):159-165.
257. Ambros V. The functions of animal microRNAs. Nature 2004, 431(7006):350-355.
258. Lee E.J., Gusev Y., Jiang J., et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007, 120(5):1046-1054.
259. Szafranska A.E., Davison T.S., John J., et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26(30):4442-4452.
260. Bloomston M., Frankel W.L., Petrocca F., et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297(17):1901-1908.
261. Lujambio A., Calin G.A., Villanueva A., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008, 105(36):13556-13561.
262. du Rieu M.C., Torrisani J., Selves J., et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010, 56(4):603-612.
263. Hanoun N., Delpu Y., Suriawinata A.A., et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem 2010, 56(7):1107-1118.
264. Habbe N., Koorstra J.B., Mendell J.T., et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009, 8(4):340-346.
265. Visone R., Petrocca F., Croce C.M. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology 2008, 135(6):1866-1869.
266. Honda M., Kaneko S., Kawai H., Shirota Y., Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001, 120(4):955-966.
267. Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006, 44(5):1122-1138.
268. Ura S., Honda M., Yamashita T., et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49(4):1098-1112.
269. Ladeiro Y., Couchy G., Balabaud C., et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47(6):1955-1963.
270. Varnholt H., Drebber U., Sculze F., et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47(4):1223-1232.
271. Yoo S.O., Chun S.M., Han E.H., et al. Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol 2011, 42(10):1391-1400.
272. Gao P., Wong C.C., Tung E.K., Lee J.M., Wong C.M., Ng I.O. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011, 54(6):1177-1184.
273. Lynn F.C. Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 2009, 20(9):452-459.
274. Esau C., Davis S., Murray S.F., et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006, 3(2):87-98.
275. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309(5740):1577-1581.
276. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327(5962):198-201.
277. Chen Y., Shen A., Rider P.J., Yu Y., et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011, 25(12):4511-4521.
278. Wu F.L., Jin W.B., Li J.H., Guo A.G. Targets for human encoded microRNAs in HBV genes. Virus Genes 2011, 42(2):157-161.
279. Novellino L., Rossi R.L., Bonino F., et al. Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLoS One 2012, 7(3):e31952.